{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-024665","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2021-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.138074+00:00","generated_at":"2026-06-28T22:48:39.384767+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Protagenic Therapeutics resolves Nasdaq audit committee compliance issue, appoints Joshua Silverman","bullets":["Nasdaq notified the Company of audit committee composition non-compliance from April 27 to September 30, 2021.","Dr. Jennifer Buell resigned from the Audit Committee; Joshua Silverman appointed effective October 1, 2021.","With Silverman's appointment, the Company is now in compliance with Nasdaq Listing Rule 5605(c)(2)(A).","It was later determined that Dr. Buell met independence requirements; she remains an independent board member."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-024665","json":"https://secwatch.observer/filing/0001493152-21-024665.json","markdown":"https://secwatch.observer/filing/0001493152-21-024665.md","text":"https://secwatch.observer/filing/0001493152-21-024665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000149315221024665/0001493152-21-024665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000149315221024665/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T22:48:39.384767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}